

RESEARCH ARTICLE

Open Access



Shiga toxin-producing *escherichia coli* infections in Norway, 1992–2012: characterization of isolates and identification of risk factors for haemolytic uremic syndrome

Lin T. Brandal^{1,6*}, Astrid L. Wester¹, Heidi Lange², Inger Løbersli¹, Bjørn-Arne Lindstedt³, Line Vold² and Georg Kapperud^{4,5}

Abstract

Background: Shiga toxin-producing *E. coli* (STEC) infection is associated with haemolytic uremic syndrome (HUS). Therefore Norway has implemented strict guidelines for prevention and control of STEC infection. However, only a subgroup of STEC leads to HUS. Thus, identification of determinants differentiating high risk STEC (HUS STEC) from low risk STEC (non-HUS STEC) is needed to enable implementation of graded infectious disease response.

Methods: A national study of 333 STEC infections in Norway, including one STEC from each patient or outbreak over two decades (1992–2012), was conducted. Serotype, virulence profile, and genotype of each STEC were determined by phenotypic or PCR based methods. The association between microbiological properties and demographic and clinical data was assessed by univariable analyses and multiple logistic regression models.

Results: From 1992 through 2012, an increased number of STEC cases including more domestically acquired infections were notified in Norway. O157 was the most frequent serogroup (33.6 %), although a decrease of this serogroup was seen over the last decade. All 25 HUS patients yielded STEC with *stx2*, *eae*, and *ehxA*. In a multiple logistic regression model, age ≤ 5 years (OR = 16.7) and *stx2a* (OR = 30.1) were independently related to increased risk of HUS. *eae* and hospitalization could not be modelled since all HUS patients showed these traits. The combination of low age (≤ 5 years) and the presence of *stx2a*, and *eae* gave a positive predictive value (PPV) for HUS of 67.5 % and a negative predictive value (NPV) of 99.0 %. SF O157:[H7] and O145:H?, although associated with HUS in the univariable analyses, were not independent risk factors. *stx1* (OR = 0.1) was the sole factor independently associated with a reduced risk of HUS (NPV: 79.7 %); *stx2c* was not so.

Conclusions: Our results indicate that virulence gene profile and patients' age are the major determinants of HUS development.

* Correspondence: lin.thorstensen.brandal@fhi.no

¹Department of Foodborne Infections, The Norwegian Institute of Public Health, Oslo, Norway

⁶Division of Infectious Disease Control, Department of Foodborne Infections, Norwegian Institute of Public Health, P.O. Box 4404, Nydalen N-0403Oslo, Norway

Full list of author information is available at the end of the article

Background

Shiga toxin-producing *Escherichia coli* (STEC), also called verocytotoxin-producing *E. coli* (VTEC), can lead to mild, self-limiting diarrhoea, haemorrhagic colitis or the life threatening complication haemolytic uremic syndrome (HUS). Children less than five years of age, the elderly, and immunocompromised persons, are most susceptible to STEC infection as well as to severe complications [1]. An association between the Shiga Toxin-encoding gene *stx2*, particularly the subtypes *stx2a*, *stx2c*, and *stx2d*, and development of HUS has been described [2–10]. Several other virulence factors that contribute to the pathogenicity of STEC have been identified, such as *eae* (*E. coli* attaching and effacing) encoding intimin and the plasmid-borne *ehxA* encoding enterohaemolysin [11]. In several parts of the world O157 is the predominating STEC serogroup, and this variant has most frequently been associated with HUS and outbreaks [12–16]. In other countries, however, like continental Europe and Scandinavia, non-O157 serogroups are dominating [3, 17–20]. The involvement of STEC in serious outbreaks combined with a high disease burden per case [21] makes STEC a significant challenge to public health.

In 1995, STEC infection was made mandatory notifiable to the Norwegian Surveillance System for Communicable Diseases (MSIS) (<http://www.msis.no>), and in 2006 diarrhoea-associated HUS became notifiable. Norway has implemented strict guidelines for prevention and control of STEC infection, in which 3–5 negative stool cultures are required for high-risk groups [22].

A few previous studies have investigated risk factors for development of HUS, however these studies have mainly focused on clinical and demographic parameters among patients infected with either serogroup O157 or O104 [23–25]. Although it is well documented that the presence of *stx2* and *eae* as well as being a child are risk determinants of HUS development, few studies have performed multivariable analyses of both O157 and non-O157 STEC to identify factors independently associated with HUS. Furthermore, knowledge of factors independently associated with reduced risk of HUS is sparse.

The main aim of the present study was to identify microbiologic and patient-related criteria differentiating HUS STEC from non-HUS STEC, in order to obtain information enabling revision of the strict control and prevention measures presently employed in Norway. The second aim was to describe human STEC infections in Norway during two decades (1992–2012), to compare with studies from other countries and contribute to our understanding of this infection in general.

Methods

Surveillance of STEC infections in Norway

Epidemiological and clinical information about STEC infection in Norway from 1992 through 2012 was obtained from MSIS at the National Institute of Public Health (NIPH), which has received mandatory notifications from medical microbiological laboratories and physicians in the country since 1995 (<http://www.msis.no/>). During this period, 513 STEC infections were notified (Fig. 1) (annual mean, 0.54 cases per 100.000 populations). Cases were recorded as domestic if the patients did not report foreign travel in the incubation period, and as imported if the patients became ill while being abroad or shortly after their return home.

Characterization of STEC isolates

All isolates were obtained from the National STEC Culture Collection at the Reference Laboratory for Enteropathogenic Bacteria at the NIPH, which receives all presumptive STEC isolates from medical microbiological laboratories throughout Norway.

We selected one isolate per patient and per outbreak, except for one patient from whom two isolates were included since they showed different virulence gene profiles and genotypes. Likewise, only one isolate was selected if isolates with identical genotype were received within the same time period from two patients with different surnames, but living within the same municipality or county, had attended the same child-care facility, or had identical travel history. Nine isolates were from asymptomatic carriers. In total, 334 STEC isolates from 333 patients (64.8 %, 333/513) were included in the study (Fig. 1).


Eighty-three out of the 334 STEC isolates, all from patients living in one of the 19 counties in Norway, have been described previously [26].

Serotyping

Presumptive STEC isolates submitted to the Reference Laboratory at NIPH were serotyped by slide agglutination using antisera against 43 different O groups (Institut für Immunpräparate und Nährmedien GmbH Berlin (SIFIN), Germany, and Statens Serum Institute (SSI), Denmark) and eight H groups (SSI, Denmark). Non-agglutinating isolates were re-tested by molecular serotyping, in which PCR was run to amplify the *wzx* or *wzy* genes of 14 O groups (O26, O86, O91, O103, O104, O111, O113, O114, O117, O121, O128, O145, O146, and O157) and the *fliC* gene of 10 H groups (H2, H4, H7, H8, H10, H11, H19, H21, H25, and H28) (Lindstedt *et al.*, unpublished).

Sorbitol-fermenting (SF) *E. coli* O157

All STEC isolates belonging to serogroup O157 were analysed with a multiplex PCR (M-PCR) specific for SF



E. coli O157 [27] in order to distinguish SF O157 STEC from the classical non-sorbitol fermenting (NSF) O157 STEC.

Virulence genes characterization

From 1992 to 2001, production of Stx1 and Stx2 was ascertained using the GM1 ganglioside enzyme-linked immunosorbent assay (GM1-ELISA) with some minor modifications [28]. In 2001 the ELISA was replaced by a M-PCR detecting *stx1* and *stx2* [29]. The same year a PCR detecting *eae* was also included [30, 31]. Since July 2005 an octaplex-PCR [32], later expanded to an endecaplex-PCR, was used for routine screening of all enteropathogenic *E. coli*. This encompassed primers for *stx1*, *stx2*, *eae*, *ehxA*, *bfpB* and *rrs* [33], as well as primers for *ipaH* [34], *LTI* (F-primer; GTT TTA TTT ACG GCG TTA CTA TCC and R-primer; ATT GGG GGT TTT ATT ATT CC), *STIa* [35], *STIb* [35], and *aggR* [34]. All STEC isolates confirmed before July 2005 were re-tested for *eae* and *ehxA* using the PCR primers described by Brandal et al. [33].

stx subtyping

Subtypes of *stx1* were identified by PCR as described by Scheutz et al. [8]. Subtyping of *stx2* was performed with one of the two following methods. The first method used PCR restriction fragment length polymorphism (RFLP) followed by electrophoresis (modification of Russmann et al. [36] and Jelacic et al. [37]), and sequencing [7], in which all *stx2d* positive isolates were verified by a *stx2d*

specific PCR [38]. The second method determined *stx2* subtypes by PCR as described by Scheutz et al. [8].

Genotyping

The O157 isolates were genotyped by an O157 specific multi-locus variable-number tandem repeat analysis (MLVA) [39]. All non-O157 STEC isolates were genotyped using a seven loci generic MLVA [40] or an updated 10 loci generic MLVA [41].

Statistical methods

Statistical analyses were performed using the computer program SPSS® release 20.0.0 (IBM SPSS Software, International Business Machines Corp., Armonk New York). Univariable analyses were performed with the procedures for cross tables (dichotomous variables) or comparison of means (continuous variables) as appropriate. Binary logistic regression was implemented for multivariable analyses. The results are reported as odds ratios with 95 % confidence intervals and two-tailed *p* values. A *p* value of ≤ 0.05 was considered statistically significant. Positive and negative predictive values were calculated as described by Altman & Bland [42].

Ethical considerations

At the NIPH, all STEC strains are routinely collected for disease surveillance and outbreak detection. The current study is based on descriptive analysis of bacterial isolates from the strain collection and the microbiological characteristics so obtained could only be combined with the

sex, age, clinical outcome, hospitalization, travel history, and seasonality for the patients from which the strains were isolated. Ethical approval was therefore not required. Also, the Norwegian Communicable Disease Control Act and its accompanying regulations (<https://lovdata.no/dokument/NL/lov/1994-08-05-55?q=Smittevernloven>) obliges the NIPH to perform national surveillance of communicable diseases, including STEC infection. For these reasons, consent was not obtained from the patients to analyze the bacterial samples for this research project.

Results

STEC infections in Norway

From 1992 to 2006, 0–20 STEC cases were notified each year, whereas from 2006 the number of notified cases increased, ranging from 22 to 111 annually (mean 54.9) (Fig. 1). Of the 513 patients recorded by surveillance, 57

developed HUS (11.1 %), and isolates from 36 of them were submitted to the National Reference Laboratory at NIPH. The major outbreaks reported in Norway during 1992 through 2012 are presented in Additional file 1.

Demographics and clinical presentation

The mean age of the 333 patients selected for the study was 24.6 years and 39.0 % (130/333) were ≤ 5 years old. Diarrhoea was the most frequent clinical manifestation, and 35.7 % (119/333) reported bloody diarrhoea (Table 1). Twenty-five of the patients (7.5 %) developed HUS (Additional file 2). Furthermore, 49.8 % had reportedly acquired their infection in Norway (Table 1), but a higher proportion of domestically acquired STEC infections was observed from 2006 compared to previous years (127/190, 66.8 % (from 2006) versus 39/83, 46.7 % (before 2006), $p < 0.005$).

Table 1 Association between patient-related factors in O157 versus non-O157 and HUS versus non-HUS STEC infections, Norway 1992–2012

Characteristics		No. (%) of patients						
		All (333)	O157 (112, 33.6 %)	Non-O157 (221, 66.4 %)	p-value ^a	HUS (25, 7.5 %)	Non-HUS (308, 92.5 %)	p-value
Sex	Male	146 (43.8 %)	47	99		9	137	
	Female	187 (56.2 %)	65	122		16	171	
Age group (yr)	≤ 5	130 (39.0 %)	25	105	<0.005	22	108	<0.005
	6–18	41 (12.3 %)	16	25		2	39	
	19–41	76 (22.8 %)	30	46		0	76	
	42–64	51 (15.4 %)	23	28		0	51	
	≥ 65	35 (10.5 %)	18	17		1	34	
Age mean		24.6	33.9	20.33	<0.005	4.72	26.2	<0.005
HUS	Yes	25 (7.5 %)	9	16		25	0	
	No	308 (92.5 %)	103	205		0	308	
Clinical outcome	Bloody diarrhea	119 (35.7 %)	40	79		13	106	<0.005
	Diarrhea	148 (44.4 %)	57	91		1	147	<0.005
	Asymptomatic	9 (2.7 %)	0	9		0	9	
	Unknown	57 (17.1 %)	15	42		11	46	
Hospitalized	Yes	141 (42.2 %)	64	77		24	117	
	No	155 (46.4 %)	39	116	<0.005	0	155	<0.005
	Unknown	37 (11.1 %)	9	28		1	36	
Travel history	Domestically	166 (49.8 %)	40	126		16	150	
	Imported	107 (32.1 %)	57	50	<0.005	3	104	
	Unknown	60 (18.0 %)	15	45		6	54	
Seasonality ^b	Summer	118 (35.4 %)	50	68		6	112	
	Autumn	74 (22.2 %)	20	54		9	65	
	Winter	75 (22.5 %)	24	51		7	68	
	Spring	66 (19.8 %)	18	48		3	63	

^aOnly p-values ≤ 0.05 were shown

^bSummer; June–August, Autumn; September–November, Winter; December–February, Spring; March–May

Characterization of selected STEC

Serogroups

Twenty-four different O groups were identified among 292 of the 334 STEC isolates examined from 333 patients. The remaining 42 isolates were non-typable with the methods employed (one of these was rough). The majority of the isolates (69.5 %, 232/334) were motile, and nine H groups were discerned. Thus, a total of 58 different O and H combinations were identified.

O157 was the most frequent serogroup detected (112/333, 33.6 %) (Table 1). The percentage of serogroup O157 significantly decreased from 49.6 % (65/131) during 1992–2006, to 23.3 % (47/202) in 2007–2012 ($p < 0.005$). Compared to non-O157, O157 infection was significantly associated with older age, foreign travel prior to disease onset, and a higher rate of hospitalization. No statistical significant differences between O157 and non-O157 infected persons were detected regarding clinical outcome (Table 1).

Serogroup O157 included 103 isolates that were NSF and nine that were SF. NSF O157 infections were more likely to occur during summer and spring, whereas infections with SF O157 were associated with colder months of the year. None of the patients with SF O157 infection reported foreign travel prior to onset of disease (Additional file 3). In a multivariable model, both foreign travel and seasonality (summer) were independently

related to NSF O157 infection (OR = 4.4, CI = 2.5–7.5 and OR = 1.9, CI = 1.1–3.3, respectively).

Non-O157 STEC infection was detected in 66.4 % of the patients (221/333) (Table 1). The most common serogroups were O103 (15.0 %), O26 (10.2 %), O145 (7.2 %), O91 (3.9 %), O117 (3.3 %), O121 (2.1 %), O113 (1.8 %), O146 (1.8 %), and O111 (1.2 %). Infection with STEC O103, O26, or O121 was associated with younger age. Additionally, patients infected with O103 or O145 were less likely to report foreign travel prior to infection (Additional file 3).

Virulence genes

Of the 334 STEC from 333 patients, 127 (38.1 %) carried *stx1* only, 118 (35.3 %) harboured *stx2* only, and 89 (26.6 %) exhibited both *stx1* and *stx2*. Thus, isolates from 215 patients (64.6 %) were positive for *stx1* and 207 (62.2 %) carried *stx2* (Table 2). None of the *stx1* positive isolates harboured more than one *stx1* subtype. *stx1a* was the most frequently detected subtype. Of the patients with *stx2* positive STEC, 100 (48.3 %) contained *stx2c* and 85 (41.1 %) carried *stx2a*. Nearly three-fourths of the patients had an *eae* positive STEC and the majority of the cases harboured STEC with *ehxA* (Table 2).

Patients with O157 and non-O157 STEC did not differ with regard to presence of *stx1* (Table 2). However, when

Table 2 Association between virulence genes, serogroups, HUS, and hospitalization among 333 cases of STEC infection, Norway 1992–2012

Virulence genes	No. (%) of patients				p-value ^a	HUS		p-value	Hospitalized ^b	
	All (333)	O157 (112, 33.6 %)	Non-O157 (221, 66.4 %)			(25, 7.5 %)	Non-HUS (308, 92.5 %)		(141, 42.3 %)	
<i>stx1</i>	215 (64.7 %)	66	150		1 ^c	214	<0.005	83	0.01	
<i>stx1a</i>	189	66	123		1	188	<0.005	75		
<i>stx1c</i>	23	0	23	<0.005	0	23		7		
<i>stx1d</i>	3	0	3		0	3		1		
<i>stx2</i>	207 ^d (62.2 %)	109	98	<0.005	25 ^e	182	<0.005	106	<0.005	
<i>stx2a</i>	85	32	53		24	61	<0.005	51	<0.005	
<i>stx2b</i>	32	0	32	<0.005	0	32		6	0.05	
<i>stx2c</i>	100	92	8	<0.005	2	98	0.01	57	<0.005	
<i>stx2d</i>	9	1	8		0	9		4		
<i>stx2g</i>	2	0	2		0	2		ND ^f		
<i>eae</i>	246 (73.9 %)	112	134	<0.005	25	220	<0.005	117	0.02	
<i>ehxA</i>	283 (85.0 %)	109	174	<0.005	25	258		131	<0.005	

^aOnly p-values ≤ 0.05 were shown

^bNo information on hospitalization was available for 37 patients. These patients carried STEC with the following *stx* genes; *stx1a* (n = 17), *stx1c* (n = 1), *stx1d* (n = 2), *stx2a* (n = 6), *stx2b* (n = 9), *stx2c* (n = 10), and *stx2g* (n = 2) (n = number of patients) (some patients carried STEC with more than one *stx* subtype)

^cFrom one HUS patient two different non-O157 STEC isolates were included. One with *stx1a* and another with *stx1a* + *stx2a* and this patient was included both in the *stx1* and *stx1a* groups as well as in the *stx2* and *stx2a* groups

^dIncluding 21 patients with STEC harbouring more than one *stx2* subtype; *stx2a* + *stx2c* (n = 19), *stx2a* + *stx2d* (n = 1), and *stx2c* + *stx2d* (n = 1)

^eOne HUS patient carried a STEC with both *stx2a* + *stx2c* and this patient was included within the *stx2a* group as well as in the *stx2c* group

^fND: not determined

stx1 was stratified according to subtypes, *stx1c* was more frequently detected among patients with non-O157 STEC, and neither *stx1c* nor *stx1d* was found in any of the patients with O157 isolates (Table 2, Additional file 4).

Nearly all patients with O157 isolates carried *stx2*, while less than half of their non-O157 counterparts had this gene. Among the *stx2* subtypes, *stx2c* and *stx2a + stx2c* were both more common in O157 ($p < 0.005$ for each), whereas *stx2b* and *stx2g* were only detected in the non-O157 group (Table 2, Additional file 4).

Both *eae* and *ehxA* were more frequently detected in O157 compared to non-O157 (Table 2).

Within O157, NSF O157 were associated with *stx2*, *eae* and *ehxA*, whereas SF O157 were less likely to harbour *stx1* (Additional file 3).

Among non-O157 isolates, O103 was more likely to carry *stx1* than the other serogroups combined, while in O145 or O121 *stx1* was infrequent. All O91, O113, and O146 isolates were *eae* negative, and only two of the O117 isolates carried this gene (Additional file 3).

Patients with *stx1* positive STEC showed a reduced risk of hospitalization, whereas the contrary was seen for patients with *stx2*, *eae*, and *ehxA* (Table 2).

Discrimination between HUS and non-HUS STEC

All 25 HUS patients, except three, were ≤ 5 years. Compared to non-HUS cases, patients with HUS were more often hospitalized and showed bloody stools (Table 1).

Seven serogroups were found among STEC from HUS patients: O157 (including both NSF O157 and SF O157 isolates), O145, O26, O103, O121, O111, and O86 (Additional file 2), however only serogroups SF O157 and O145 were significantly associated with HUS (Table 3 and Additional file 3). Within serogroup O145, four of the six patients with STEC O145:H? presented with HUS ($p < 0.005$, PPV:66.7 %, NPV:93.6 %), whereas only one of eighteen patients with O145:H28 showed this complication. No significant association between HUS and serogroup O103 was seen, but all three patients with STEC O103:H25 developed HUS.

All HUS patients carried STEC with *stx2*, *eae*, and *ehxA*, however only *stx2* and *eae* were significantly associated with HUS, while *ehxA* was not (Table 2 and 3). *stx2a* was present in 24/25 HUS STEC (including one with *stx2a + stx2c*), whereas the last case carried *stx2c* only. Both *stx1* and *stx2c* were negatively associated with HUS (Table 2 and 3). The combination of age ≤ 5 years and STEC possessing *stx2a* and *eae* showed strong

Table 3 Risk factors for HUS among 333 STEC patients, Norway, 1992–2012

Determinant ^a	No. of patients		Predictive values ^b		Univariable analyses ^c OR (95 % CI)	Multivariable analyses ^{c, d}		
	All (333)	HUS (25)	PPV	NPV		Model 1 (risk factors) OR (95 % CI)	Model 2 (preventive factors) OR (95 % CI)	Model 3 (all factors) OR (95 % CI)
	Age ≤ 5 yr	130	22	16.9 %		98.5 %	13.6 (4.0-46.4)	12.2 (3.2-46.7)
Bloody diarrhea	119	13	10.9 %	99.4 %	19.5 (2.5-151.3)	ND ^e		
Diarrhea	148	1	0.7 %	78.1 %	0.1 (0.008-0.5)		ND	
Hospitalized ^f	141	24	17.0 %	100.0 %	ND			
SF O157	9	5	55.6 %	93.8 %	19.0 (4.7-76.3)	NS ^g		
O145	24	5	20.8 %	93.5 %	3.8 (1.3-11.2)			
O145:H?	6	4	66.7 %	93.6 %	29.1 (5.0-168.4)	NS		
<i>stx1</i>	215	1 ^h	0.5 %	79.7 %	0.02 (0.002-0.1)		0.02 (0.002-0.1)	0.1 (0.01-0.8)
<i>stx1a</i>	189	1 ^h	0.5 %	83.3 %	0.03 (0.004-0.2)			
<i>stx2</i>	207	25	12.1 %	100.0 %	ND			
<i>stx2a</i>	85	24	28.2 %	99.6 %	97.2 (12.9-732.5)	92.7 (10.7-803.5)		30.1 (3.3-271.9)
<i>stx2c</i>	100	2	2.0 %	90.1 %	0.2 (0.04-0.8)		0.2 (0.03-0.7)	0.6 (0.1-3.3)
<i>eae</i>	245	25	10.2 %	100.0 %	ND			

^aAll determinants associated with HUS ($p \leq 0.05$) were included

^bPPV; positive predictive value, NPV; negative predictive value

^cOR; odds ratio, CI; 95 % confidence interval

^dModel 1; factors related to increased risk of developing HUS, Model 2; factors related to reduced risk of HUS, and Model 3; comprising both factors related to increased and decreased risk of HUS

^eND; not determined since all HUS cases were hospitalized and all HUS isolates carried *stx2* and *eae*

^fInformation on hospitalization was not available for 37 patients, including one HUS patient

^gNS; not statistically significant

^hOne HUS patients had two STEC isolates; one with *stx1a + stx2a* and another with *stx1a* only

association to HUS development with PPV of 64.7 % and NPV of 99.0 %. Additionally, this combination gave the highest sensitivity (88.0 %) and specificity (96.1 %) of all determinants investigated (data not shown).

Three multivariable models were fitted, with and without including potentially protective factors. In the first model, two factors were found to be independently related to increased risk of developing HUS: *stx2a* (OR = 92.7, CI = 10.7-803.5) and age \leq 5 years (OR = 12.2, CI = 3.2-46.7). In this model, the following factors were not independently associated with HUS: SF O157 and O145:H?, although they were significant in the univariable analysis (Table 3). No first-order interactions were detected in the model. All HUS patients with bloody diarrhoea carried STEC with *stx2a*, and bloody diarrhoea was therefore not included in the model containing *stx2a*. Furthermore, *eae*, *stx2*, and hospitalization could not be modelled since all HUS patients showed this trait (for one HUS patient no information on hospitalization was available).

In a separate model assessing protective factors only, both *stx1* (OR = 0.02, CI = 0.002-0.1) and *stx2c* (OR = 0.2, CI = 0.03-0.7) were independently associated with reduced risk of HUS (Table 3). Non-bloody diarrhoea was not included in the model as only one HUS patient showed this symptom. In the third model comprising *stx2a*, age, *stx1* and *stx2c*, *stx1* was still related to reduced risk of HUS development (OR = 0.1, CI = 0.01-0.8), whereas *stx2c* was not (OR = 0.6, CI = 0.1-3.3) (Table 3).

Discussion

Low age (\leq 5 years), and the presence of STEC with *stx2a* and *eae* were identified as risk factors for HUS development. An association between HUS and these parameters has been seen in several studies [2–10, 16–18, 43], however, only a few have explored this by multivariable analysis [2, 7, 44]. The high NPV (99.0 %) obtained for this combination of determinants indicates that the likelihood of developing HUS is very low when all these factors are negative. However, not all patients with these three risk factors developed HUS (PPV of 64.7 %), emphasizing that other strain characteristics or host specific factors, like the patient's immunocompetence, also are important to consider when assessing a patients' risk for developing HUS. Bloody diarrhoea has previously been identified as a risk factor for HUS [2], and a similar association was achieved in our study, although not proven as an independent risk factor. Interestingly, when only including protective factors in a multivariable model, *stx2c* was independently associated with reduced risk of HUS, but not when both protective and risk factors were included in the same model. The role of *stx2c* in HUS pathogenesis has been debated and it has been speculated that *stx2c* merely assists *stx2a* during development of this severe complication [7]. However, our results

indicated that *stx2c* neither was sufficient nor necessary for HUS development. In one of the two HUS patients with *stx2c* positive STEC, *stx2c* and *stx2a* were both present, whereas in the second case *stx2c* was the sole *stx* gene detected. It is possible, though, that this isolate had lost the *stx2a* encoding bacteriophage, a phenomenon previously described in isolates from HUS patients [45, 46]. *stx1* was independently related to reduced risk of HUS in two multivariable models. This has to our knowledge never been shown before, although such an association has been suggested [3, 16, 26, 47–50]. None of the HUS patients carried STEC with *stx1* as the sole *stx* gene present. The single HUS patient with *stx1* yielded two O111:[H8] isolates, one with *stx1a* + *stx2a* and the other with *stx1a* only, indicating that *stx2a* was the *stx* gene responsible for HUS development. Recently, it was demonstrated that STEC O111:H8 strains frequently lose their *stx2* encoding bacteriophage during *in vitro* growth, suggesting that this loss may occur *in vivo* as well [3, 51]. Moreover, *stx1* showed a low PPV for HUS, a finding which further emphasises that *stx1* was not a key factor for HUS development.

In contrast to some authors [3, 15, 16, 52], but in concordance with others [2, 7], we did not find any significant difference between STEC O157 and non-O157 regarding HUS. Interestingly, of the O157 STEC isolated from HUS patients, SF O157 was the dominating variant, despite the fact that NSF O157 was the most frequent STEC detected in Norway. A high frequency of SF O157 in HUS cases has also been reported from other European countries [9, 53] and it has been suggested that patients with STEC SF O157 more often develop HUS compared to patients with NSF O157 [54, 55]. Furthermore, SF O157 and O145 (particularly O145:H?) were the only serogroups associated with HUS in our univariable analyses, although they were not significant in the multivariable models. All STEC O145:H? and SF O157 cases were domestically acquired, indicating a reservoir of these bacteria in Norway. Both serogroups have previously been responsible for HUS outbreaks in our country [56].

Our results confirm that the severity of STEC illness depends strongly on the virulence gene profile of the infecting STEC as well as the patients' age, unlike serogroup affiliation [2, 57, 58]. Nevertheless, exceptions exist and therefore clinical findings and the epidemiological situation of each STEC case have to be considered before proper control and prevention measures can be implemented.

In Norway infections with non-O157 STEC were more common than infections with O157 isolates, in concordance with findings from several other countries [3, 17–19, 59–61]. Expectedly, the proportion of STEC O157 declined compared to non-O157 from approximately

2007, when improved methods for detecting *stx*/*Stx* were implemented in the majority of clinical microbiological laboratories in Norway [3, 16, 50, 61, 62]. In contrast to reports from other countries, more than half of the STEC O157 infections in Norway were imported and no seasonal differences between O157 and non-O157 infections were seen [16, 63, 64]. Since ruminants are the main reservoir of STEC O157 [65], the low prevalence of STEC O157 among ruminants in Norway might explain these findings [66–69]. Non-O157 infections were more frequently seen in children (≤ 5 years) and were more often domestically acquired than O157 infections. Contact with ruminants has previously been identified as the strongest risk factor for non-O157 infection in young children [70] and the following data indicate that this might be the case also in Norway: A national survey of Norwegian sheep flocks [69] showed that as many as 17.3 % (85/491) of the flocks carried non-O157 *E. coli* considered to be human pathogens (unpublished data). Also, non-O157 STEC outbreaks associated with sheep contact or eating mutton have been reported in Norway [71, 72].

There are some limitations to our study. Firstly, we did not examine a consecutive series of STEC isolates from the National STEC Culture Collection, but selected one STEC per patient and per outbreak. Therefore a correct incidence of STEC isolates was not achieved. However, the main aim of our study was to define factors discriminating HUS-STECS from non-HUS STECS. Inclusion of all STEC isolates would have given a biased contribution of the different parameters due to overrepresentation of isolates involved in outbreaks. Secondly, it is likely that non-O157 STECS were underestimated before 2007 since the sensitivity of diagnostic methods were suboptimal at that time. Although the laboratory methods have improved, non-O157 STEC isolation is still a diagnostic challenge due to lack of a selective growth media with sufficient sensitivity. Thirdly, the number of HUS cases included in the study was too low to identify other than the strongest risk factors. Finally, the available clinical information did not permit detailed analysis of patient-related factors such as underlying illnesses, antibiotic treatment, and co-infections, all of which have been considered as putative risk factors for HUS.

Conclusions

Our results showed that the characteristics of the Norwegian STEC isolates were in concordance with data from other countries. However, some country specific characteristics were unravelled. Multivariable regression analyses identified low age (≤ 5 years) and the presence of *stx2a* as independent risk factors for HUS development. Additionally, all HUS STECS carried *eae*. On the other hand, *stx1* was independently associated with reduced risk of HUS. Hence, the virulence profile and the patients' age - but not particular serogroups - were the essential determinants

discriminating HUS STECS from non-HUS STECS. The results achieved from the current study will contribute, together with previous published knowledge, to revision of the strict national guidelines for prevention and control of STEC infections currently applied in Norway. Nevertheless, it should be emphasized that in addition to the risk factors identified, the clinical presentation of each patient and the epidemiological context also should be taken into account before advice of control and prevention can be given.

Additional files

Additional file 1: Reported outbreaks of human STEC infections, Norway 1992–2012. Characteristics of both local and nationwide STEC outbreaks detected in Norway from 1992–2012.

Additional file 2: STEC isolates from HUS patients included in the present study, Norway 1992–2012. Microbiological characteristics of STEC isolates ($n = 26$) from haemolytic uremic syndrome (HUS) patients and characteristics of patients with HUS ($n = 25$) in Norway from 1992–2012.

Additional file 3: Characteristics associated with the most common STEC serogroups, Norway 1992–2012. Demographic, clinical, and virulence characteristics among STEC harbouring the most common serogroups, Norway from 1992–2012.

Additional file 4 Distribution of *stx* genotypes in STEC O157 compared to non-O157 STEC, Norway 1992–2012. Distribution and combination of *stx1* and *stx2* subtypes in STEC O157 compared to non-O157 STEC, Norway from 1992–2012.

Abbreviations

CI: Confidence interval; *eae*: *E. coli* attaching and effacing; *ehxA*: Enterohaemolysin; HUS: Haemolytic uremic syndrome; NIPH: Norwegian Institute of Public Health; NPV: Negative predictive value; NSF: Non-sorbitol fermenting; MLVA: Multiple-locus variable-number of tandem repeat analysis; MSIS: The National Surveillance System for Communicable Diseases; OR: Odds ratio; PPV: Positive predictive value; SF: Sorbitol-fermenting; STEC: Shiga toxin-producing *E. coli*; *Stx*: Shiga toxin; VTEC: Verocytotoxigenic *E. coli*.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LTB led the design of the study and writing of the manuscript. All authors contributed to the writing and reviewing of the paper. LTB, ALW, LV, and GK were involved in the project design. LTB, ALW, IL, and BAL participated in the design, analyses, and interpretation of the microbiological data. HL and LV were responsible for the patient-related data. GK performed the statistical analyses. LTB, ALW, HL, and GK interpreted the statistical data. All authors read and approved the final manuscript.

Acknowledgements

We want to thank the staff at the Department of Foodborne Infections at the Norwegian Institute of Public Health for skilful technical assistance, including Torbjørn Bruvik who was involved in molecular serotyping and *stx* subtyping. We also would like to thank Kirsten Konsmo at the Department of Infectious Disease Epidemiology at the Norwegian Institute of Public Health for quality assurance of the MSIS data. Finally, we will thank all medical microbiological laboratories in Norway for the tremendous work load put into isolating STEC from patient samples and forwarding the isolates to the NIPH for further characterization. Infection control of STEC on both the local and national level relies heavily on their efforts.

Author details

¹Department of Foodborne Infections, The Norwegian Institute of Public Health, Oslo, Norway. ²Department of Infectious Disease Epidemiology, The Norwegian Institute of Public Health, Oslo, Norway. ³Gene Technology Section, Akershus University Hospital, Lørenskog, Norway. ⁴Division of

Infectious Disease Control, The Norwegian Institute of Public Health, Oslo, Norway. ⁵Department of Food Safety and Infection Biology, Norwegian University of Life Sciences, Oslo, Norway. ⁶Division of Infectious Disease Control, Department of Foodborne Infections, Norwegian Institute of Public Health, P.O. Box 4404, Nydalen N-0403Oslo, Norway.

Received: 5 December 2014 Accepted: 8 July 2015

Published online: 11 August 2015

References

- Webster K, Schnitzler E. Hemolytic uremic syndrome. *Handb Clin Neurol*. 2014;120:1113–23.
- Ethelberg S, Olsen KE, Scheutz F, Jensen C, Schiellerup P, Enberg J, et al. Virulence factors for hemolytic uremic syndrome, Denmark. *Emerg Infect Dis*. 2004;10:842–7.
- Buvsen G, De Gheldre Y, Dediste A, de Moreau AI, Mascart G, Simon A, et al. Incidence and virulence determinants of verocytotoxin-producing *Escherichia coli* infections in the Brussels-Capital Region, Belgium, in 2008–2010. *J Clin Microbiol*. 2012;50:1336–45.
- Mellmann A, Bielaszewska M, Kock R, Friedrich AW, Fruth A, Middendorf B, et al. Analysis of collection of hemolytic uremic syndrome-associated enterohemorrhagic *Escherichia coli*. *Emerg Infect Dis*. 2008;14:1287–90.
- Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, et al. *Escherichia coli* harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. *J Infect Dis*. 2002;185:74–84.
- Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in *Escherichia coli* isolated from humans: predictor for a severe clinical outcome. *Clin Infect Dis*. 2006;43:1160–7.
- Persson S, Olsen KE, Ethelberg S, Scheutz F. Subtyping method for *Escherichia coli* shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. *J Clin Microbiol*. 2007;45:2020–4.
- Scheutz F, Teel LD, Beutin L, Pierard D, Buvsen G, Karch H, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. *J Clin Microbiol*. 2012;50:2951–63.
- Marejkova M, Blahova K, Janda J, Fruth A, Petras P. Enterohemorrhagic *Escherichia coli* as causes of hemolytic uremic syndrome in the Czech Republic. *PLoS One*. 2013;8:e73927.
- European Center for Disease Prevention and Control: Surveillance of food- and waterborne diseases in the EU/EEA - 2006–2009. *ECDC* 2013, [http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=900]
- Melton-Celsa A, Mohawk K, Teel L, O'Brien A. Pathogenesis of Shiga-toxin producing *Escherichia coli*. *Curr Top Microbiol Immunol*. 2012;357:67–103.
- Vally H, Hall G, Dyda A, Raupach J, Knope K, Combs B, et al. Epidemiology of Shiga toxin producing *Escherichia coli* in Australia, 2000–2010. *BMC Public Health*. 2012;12:63.
- Rivero MA, Passucci JA, Rodriguez EM, Parma AE. Seasonal variation of HUS occurrence and VTEC infection in children with acute diarrhoea from Argentina. *Eur J Clin Microbiol Infect Dis*. 2012;31:1131–5.
- Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States—major pathogens. *Emerg Infect Dis*. 2011;17:7–15.
- Locking ME, Pollock KG, Allison LJ, Rae L, Hanson MF, Cowden JM. *Escherichia coli* O157 infection and secondary spread, Scotland, 1999–2008. *Emerg Infect Dis*. 2011;17:524–7.
- Gould LH, Mody RK, Ong KL, Clougher P, Cronquist AB, Garman KN, et al. Increased recognition of non-O157 Shiga toxin-producing *Escherichia coli* infections in the United States during 2000–2010: epidemiologic features and comparison with *E. coli* O157 infections. *Foodborne Pathog Dis*. 2013;10:453–60.
- Beutin L, Krause G, Zimmermann S, Kaulfuss S, Gleier K. Characterization of Shiga toxin-producing *Escherichia coli* strains isolated from human patients in Germany over a 3-year period. *J Clin Microbiol*. 2004;42:1099–108.
- Kappeli U, Hachler H, Giezendanner N, Beutin L, Stephan R. Human infections with non-O157 Shiga toxin-producing *Escherichia coli*, Switzerland, 2000–2009. *Emerg Infect Dis*. 2011;17:180–5.
- van Duynhoven YT, Friesema IH, Schuurman T, Roovers A, van Zwet AA, Sabbe LJ, et al. Prevalence, characterisation and clinical profiles of Shiga toxin-producing *Escherichia coli* in The Netherlands. *Clin Microbiol Infect*. 2008;14:437–45.
- European Food Safety Authority ECDFPaC: The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2011. *EFSA Journal* 2013;11:3129 [250 pp]. doi:10.2903/j.efsa.2013.3129 2013.
- Blaser MJ. Deconstructing a lethal foodborne epidemic. *N Engl J Med*. 2011;365:1835–6.
- Norwegian Institute of Public Health: *E. coli*-enteritt (inkludert EHEC-infeksjon og HUS). *Smittevern* 2013 [In Norwegian], [http://www.fhi.no/eway/default.aspx?pid=239&trg=Content_6493&Main_6157=6287:0:25,5499&Main_Content_6287=6493:0:25,6833&Content_6493=6441:82709:0:6446:32::0:0]
- Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, et al. Risk factors for the hemolytic uremic syndrome in children infected with *Escherichia coli* O157:H7: a multivariable analysis. *Clin Infect Dis*. 2012;55:33–41.
- Werber D, King LA, Muller L, Follin P, Buchholz U, Bernard H, et al. Associations of age and sex with the clinical outcome and incubation period of Shiga toxin-producing *Escherichia coli* O104:H4 infections, 2011. *Am J Epidemiol*. 2013;178:984–92.
- Zoufaly A, Cramer JP, Vettorazzi E, Sayk F, Bremer JP, Koop I, et al. Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC O104:H4 infection. *PLoS One*. 2013;8:e59209.
- Haugum K, Brandal LT, Lindstedt BA, Wester AL, Bergh K, Afset JE. PCR-Based Detection and Molecular Characterization of Shiga Toxin-Producing *Escherichia coli* Strains in a Routine Microbiology Laboratory over 16 years. *J Clin Microbiol*. 2014;52:3156–63.
- Haugum K, Lindstedt BA, Loberli I, Kapperud G, Brandal LT. Identification of the anti-terminator qO111(H)- gene in Norwegian sorbitol-fermenting *Escherichia coli* O157:NM. *FEMS Microbiol Lett*. 2012;329:102–10.
- Back E, Svennerholm AM, Holmgren J, Mollby R. Evaluation of a ganglioside immunosorbent assay for detection of *Escherichia coli* heat-labile enterotoxin. *J Clin Microbiol*. 1979;10:791–5.
- Brian MJ, Frosolono M, Murray BE, Miranda A, Lopez EL, Gomez HF, et al. Polymerase chain reaction for diagnosis of enterohemorrhagic *Escherichia coli* infection and hemolytic-uremic syndrome. *J Clin Microbiol*. 1992;30:1801–6.
- Gannon VP, Rashed M, King RK, Thomas EJ. Detection and characterization of the *eae* gene of Shiga-like toxin-producing *Escherichia coli* using polymerase chain reaction. *J Clin Microbiol*. 1993;31:1268–74.
- Wang G, Clark CG, Rodgers FG. Detection in *Escherichia coli* of the genes encoding the major virulence factors, the genes defining the O157:H7 serotype, and components of the type 2 Shiga toxin family by multiplex PCR. *J Clin Microbiol*. 2002;40:3613–9.
- Brandal LT, Lindstedt BA, Aas L, Stavnes TL, Lassen J, Kapperud G. Octaplex PCR and fluorescence-based capillary electrophoresis for identification of human diarrheagenic *Escherichia coli* and *Shigella* spp. *J Microbiol Methods*. 2007;68:331–41.
- Brandal LT, Sekse C, Lindstedt BA, Sunde M, Loberli I, Urdahl AM, et al. Norwegian sheep are an important reservoir for human-pathogenic *Escherichia coli* O26:H11. *Appl Environ Microbiol*. 2012;78:4083–91.
- Toma C, Lu Y, Higa N, Nakasone N, Chinen I, Baschker A, et al. Multiplex PCR assay for identification of human diarrheagenic *Escherichia coli*. *J Clin Microbiol*. 2003;41:2669–71.
- Bolin I, Wiklund G, Qadri F, Torres O, Bourgeois AL, Savarino S, et al. Enterotoxigenic *Escherichia coli* with STx and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers. *J Clin Microbiol*. 2006;44:3872–7.
- Russmann H, Schmidt H, Heesemann J, Caprioli A, Karch H. Variants of Shiga-like toxin II constitute a major toxin component in *Escherichia coli* O157 strains from patients with haemolytic uraemic syndrome. *J Med Microbiol*. 1994;40:338–43.
- Jelacic JK, Damrow T, Chen GS, Jelacic S, Bielaszewska M, Ciol M, et al. Shiga toxin-producing *Escherichia coli* in Montana: bacterial genotypes and clinical profiles. *J Infect Dis*. 2003;188:719–29.
- Zheng J, Cui S, Teel LD, Zhao S, Singh R, O'Brien AD, et al. Identification and characterization of Shiga toxin type 2 variants in *Escherichia coli* isolates from animals, food, and humans. *Appl Environ Microbiol*. 2008;74:5645–52.
- Lindstedt BA, Heir E, Gjernes E, Vardund T, Kapperud G. DNA fingerprinting of Shiga-toxin producing *Escherichia coli* O157 based on Multiple-Locus Variable-Number Tandem-Repeats Analysis (MLVA). *Ann Clin Microbiol Antimicrob*. 2003;2:12.

40. Lindstedt BA, Brandal LT, Aas L, Vardund T, Kapperud G. Study of polymorphic variable-number-of tandem repeats loci in the ECOR collection and in a set of pathogenic *Escherichia coli* and *Shigella* isolates for use in a genotyping assay. *J Microbiol Methods*. 2007;69:197–205.
41. Lobersli I, Haugum K, Lindstedt BA. Rapid and high resolution genotyping of all *Escherichia coli* serotypes using 10 genomic repeat-containing loci. *J Microbiol Methods*. 2012;88:134–9.
42. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. *BMJ*. 1994;309:102.
43. Byrne L, Vanstone GL, Perry NT, Launders N, Adak GK, Godbole G, et al. The epidemiology and microbiology of Shiga-toxin producing *Escherichia coli* other than serogroup O157 in England 2009–2013. *J Med Microbiol*. 2014;63:1181–8.
44. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producing *Escherichia coli* and disease in humans. *J Clin Microbiol*. 1999;37:497–503.
45. Bielaszewska M, Middendorf B, Kock R, Friedrich AW, Fruth A, Karch H, et al. Shiga toxin-negative attaching and effacing *Escherichia coli*: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution. *Clin Infect Dis*. 2008;47:208–17.
46. Bielaszewska M, Zhang W, Tarr PI, Sonntag AK, Karch H. Molecular profiling and phenotype analysis of *Escherichia coli* O26:H11 and O26:NM: secular and geographic consistency of enterohemorrhagic and enteropathogenic isolates. *J Clin Microbiol*. 2005;43:4225–8.
47. Pradel N, Bertin Y, Martin C, Livrelli V. Molecular analysis of shiga toxin-producing *Escherichia coli* strains isolated from hemolytic-uremic syndrome patients and dairy samples in France. *Appl Environ Microbiol*. 2008;74:2118–28.
48. Kawano K, Ono H, Iwashita O, Kurogi M, Haga T, Maeda K, et al. stx genotype and molecular epidemiological analyses of Shiga toxin-producing *Escherichia coli* O157:H7/H- in human and cattle isolates. *Eur J Clin Microbiol Infect Dis*. 2012;31:119–27.
49. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Wurzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. *Diagn Microbiol Infect Dis*. 2007;59:235–42.
50. Luna-Gierke RE, Griffin PM, Gould LH, Herman K, Bopp CA, Strockbine N, et al. Outbreaks of non-O157 Shiga toxin-producing *Escherichia coli* infection: USA. *Epidemiol Infect*. 2014;1–11.
51. Watahiki M, Isobe J, Kimata K, Shima T, Kanatani J, Shimizu M, et al. Characterization of enterohemorrhagic *Escherichia coli* O111 and O157 strains isolated from outbreak patients in Japan. *J Clin Microbiol*. 2014;52:2757–63.
52. Rivero MA, Passucci JA, Rodriguez EM, Parma AE. Role and clinical course of verotoxigenic *Escherichia coli* infections in childhood acute diarrhoea in Argentina. *J Med Microbiol*. 2010;59:345–52.
53. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic *Escherichia coli* in human medicine. *Int J Med Microbiol*. 2005;295:405–18.
54. Alpers K, Werber D, Frank C, Koch J, Friedrich AW, Karch H, et al. Sorbitol-fermenting enterohaemorrhagic *Escherichia coli* O157:H- causes another outbreak of haemolytic uraemic syndrome in children. *Epidemiol Infect*. 2009;137:389–95.
55. Rosser T, Dransfield T, Allison L, Hanson M, Holden N, Evans J, et al. Pathogenic potential of emergent sorbitol-fermenting *Escherichia coli* O157:NM. *Infect Immun*. 2008;76:5598–607.
56. Nygård K VL, Heier BT, Bruun T, Kapperud G. Annual report: Foodborne infections and outbreaks in 2009. Reporting system for infectious diseases (MSIS) and web-based system for outbreak warning (Vesuv). 2010 [In Norwegian], [http://www.fhi.no/eway/default.aspx?pid = 239&trg = Content_6466&Main_6157 = 6263:0:25,6493&MainContent_6263 = 6466:0:25,6494&Content_6466 = 6259:84108:0:6184:2::0:0]
57. Preussel K, Hohle M, Stark K, Werber D. Shiga toxin-producing *Escherichia coli* O157 is more likely to lead to hospitalization and death than non-O157 serogroups—except O104. *PLoS One*. 2013;8:e78180.
58. Gerber A, Karch H, Allerberger F, Verwey HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing *Escherichia coli* infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. *J Infect Dis*. 2002;186:493–500.
59. Pradel N, Livrelli V, De Champs C, Palcoux JB, Reynaud A, Scheutz F, et al. Prevalence and characterization of Shiga toxin-producing *Escherichia coli* isolated from cattle, food, and children during a one-year prospective study in France. *J Clin Microbiol*. 2000;38:1023–31.
60. Blanco JE, Blanco M, Alonso MP, Mora A, Dahbi G, Coira MA, et al. Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing *Escherichia coli* isolates from human patients: prevalence in Lugo, Spain, from 1992 through 1999. *J Clin Microbiol*. 2004;42:311–9.
61. Mingle LA, Garcia DL, Root TP, Halse TA, Quinlan TM, Armstrong LR, et al. Enhanced identification and characterization of non-O157 Shiga toxin-producing *Escherichia coli*: a six-year study. *Foodborne Pathog Dis*. 2012;9:1028–36.
62. Kappeli U, Hachler H, Giezendanner N, Cheasty T, Stephan R. Shiga toxin-producing *Escherichia coli* O157 associated with human infections in Switzerland, 2000–2009. *Epidemiol Infect*. 2010;1–8.
63. Hecican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, et al. Characteristics of O157 versus non-O157 Shiga toxin-producing *Escherichia coli* infections in Minnesota, 2000–2006. *Clin Infect Dis*. 2009;49:358–64.
64. Statens Serum Institut: Diaréfremkaldende *E. coli* 2000–2012. *EPI-NYT* 2014, [In Danish], [http://www.ssi.dk/Aktuelt/Nyhedsbrev/EPI-NYT/2014/Uge%2010%20-%202014.aspx]
65. Smith JL, Fratamico PM, Gunther NW. Shiga toxin-producing *Escherichia coli*. *Adv Appl Microbiol*. 2014;86:145–97.
66. Vold L, Klungseth Johansen B, Kruse H, Skjerve E, Wasteson Y. Occurrence of shigatoxinogenic *Escherichia coli* O157 in Norwegian cattle herds. *Epidemiol Infect*. 1998;120:21–8.
67. LeJeune JT, Hancock D, Wasteson Y, Skjerve E, Urdahl AM. Comparison of *E. coli* O157 and Shiga toxin-encoding genes (stx) prevalence between Ohio, USA and Norwegian dairy cattle. *Int J Food Microbiol*. 2006;109:19–24.
68. Urdahl AM, Beutin L, Skjerve E, Wasteson Y. Serotypes and virulence factors of Shiga toxin-producing *Escherichia coli* isolated from healthy Norwegian sheep. *J Appl Microbiol*. 2002;93:1026–33.
69. Urdahl AM, Bruheim T, Cudjoe K, Hofshagen M, Hopp P, Johanessen G, Sunde M. Survey of *E. coli* in sheep. *Veterinærinstituttets rapportserie* 2009, 02, [In Norwegian], [http://www.vetinst.no/Publikasjoner/Rapportserie/Rapportserie-2009/2-2009-Kartlegging-av-E.-coli-hos-sau-resultater-fra-proever-samlet-inn-i-2007]
70. Werber D, Behnke SC, Fruth A, Merle R, Menzler S, Glaser S, et al. Shiga toxin-producing *Escherichia coli* infection in Germany: different risk factors for different age groups. *Am J Epidemiol*. 2007;165:425–34.
71. Schimmer B, Nygard K, Eriksen HM, Lassen J, Lindstedt BA, Brandal LT, et al. Outbreak of haemolytic uraemic syndrome in Norway caused by stx2-positive *Escherichia coli* O103:H25 traced to cured mutton sausages. *BMC Infect Dis*. 2008;8:41.
72. Wahl E, Vold L, Lindstedt BA, Bruheim T, Afsset JE. Investigation of an *Escherichia coli* O145 outbreak in a child day-care centre—extensive sampling and characterization of eae- and stx1-positive *E. coli* yields epidemiological and socioeconomic insight. *BMC Infect Dis*. 2011;11:238.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

